Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Doebele

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Cancer Cell|October 16, 2019
Acquired Resistance Is Oncogene and Drug AgnosticRobert C Doebele
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
A nice problem to have: when ALK inhibitor therapy works better than expectedRobert C Doebele
Nature Reviews. Clinical Oncology|July 25, 2013
Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer?Robert C Doebele
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Genetic testing for lung cancer: reflex versus clinical selectionPaul A Bunn, Robert C Doebele
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung CancerChad G Rusthoven, Robert C Doebele
Nature Medicine|May 6, 2016
A framework for understanding and targeting residual disease in oncogene-driven solid cancersTrever G Bivona, Robert C Doebele
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2013
Molecular pathways: ROS1 fusion proteins in cancerKurtis D Davies, Robert C Doebele
Current Treatment Options in Oncology|September 18, 2014
The minority report: targeting the rare oncogenes in NSCLCCaroline E McCoach, Robert C Doebele
Expert Review of Clinical Pharmacology|December 19, 2017
The importance of the initial response to cancer treatment in predicting longer overall survivalCaroline E McCoach, Robert C Doebele
Drugs|April 18, 2013
Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agentsEamon M Berge, Robert C Doebele
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Cancer Cell|October 16, 2019
Acquired Resistance Is Oncogene and Drug AgnosticRobert C Doebele
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
A nice problem to have: when ALK inhibitor therapy works better than expectedRobert C Doebele
Nature Reviews. Clinical Oncology|July 25, 2013
Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer?Robert C Doebele
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Genetic testing for lung cancer: reflex versus clinical selectionPaul A Bunn, Robert C Doebele
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung CancerChad G Rusthoven, Robert C Doebele
Nature Medicine|May 6, 2016
A framework for understanding and targeting residual disease in oncogene-driven solid cancersTrever G Bivona, Robert C Doebele
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2013
Molecular pathways: ROS1 fusion proteins in cancerKurtis D Davies, Robert C Doebele
Current Treatment Options in Oncology|September 18, 2014
The minority report: targeting the rare oncogenes in NSCLCCaroline E McCoach, Robert C Doebele
Expert Review of Clinical Pharmacology|December 19, 2017
The importance of the initial response to cancer treatment in predicting longer overall survivalCaroline E McCoach, Robert C Doebele
Drugs|April 18, 2013
Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agentsEamon M Berge, Robert C Doebele
Pageof 15